Breast Cancer Archives - MPR

Breast Cancer

Kadcyla Approved as Adjuvant Treatment for HER2-Positive Early Breast Cancer

The Food and Drug Administration (FDA) has approved Kadcyla (ado-trastuzumab emtansine; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. The approval was supported by data from the phase 3 KATHERINE study which evaluated the safety and efficacy of Kadcyla vs…